UCB (OTCMKTS:UCBJF) Reaches New 12-Month High – Time to Buy?

UCB SA (OTCMKTS:UCBJF) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $317.94 and last traded at $317.94, with a volume of 186 shares changing hands. The stock had previously closed at $302.5125.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on UCBJF. Barclays restated an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Stephens reiterated an “overweight” rating on shares of UCB in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a research report on Monday, December 8th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, UCB presently has an average rating of “Buy”.

UCB Stock Performance

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The company’s 50 day simple moving average is $283.06 and its 200 day simple moving average is $257.17.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.